Free Trial
→ The REAL Reason Trump is Invading Iran (From Banyan Hill Publishing) (Ad)tc pixel
NASDAQ:ZNTL

Zentalis Pharmaceuticals Q3 2026 Earnings Date & Estimates

Zentalis Pharmaceuticals logo
$2.24 -0.08 (-3.45%)
Closing price 04:00 PM Eastern
Extended Trading
$2.24 0.00 (0.00%)
As of 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Zentalis Pharmaceuticals is estimated to report Q3 2026 earnings on Tuesday, November 10, 2026. The conference call is scheduled for November 6, 2026 at 4:00 PM ET.

Research:ProfileEarnings HistoryForecast

Upcoming Earnings Announcement

Quarter
Q3 2026
Announcement Date
Conference Call Date
Conference Call
4:00 PM ET
Google Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab)

What Analysts Expect from Zentalis Pharmaceuticals in Q3 2026

Zentalis Pharmaceuticals is expected to post earnings of -$0.58 per share. In the same quarter a year earlier Zentalis Pharmaceuticals reported -$0.37 per share. Zentalis Pharmaceuticals last reported on August 6, 2026, posting -$0.59 per share and missing the -$0.49 consensus estimate. Zentalis Pharmaceuticals has beaten the consensus EPS estimate in 4 of its last 8 quarters.

Consensus Estimates

Consensus EPS
-$0.58
Prior-Year EPS
-$0.37

Recent Track Record

Last Reported
Q2 2026
Last Quarter EPS
-$0.59 (Missed by -$0.10)
EPS Beat Rate
4 of last 8 quarters

Prepare for the Q3 2026 Call

Zentalis Pharmaceuticals Q3 2026 Earnings FAQ

Zentalis Pharmaceuticals (NASDAQ:ZNTL) is estimated to report Q3 2026 earnings on Tuesday, November 10, 2026. This date is estimated from past reporting schedules and may change once the company confirms it.

Zentalis Pharmaceuticals' Q3 2026 earnings conference call is scheduled for Friday, November 6, 2026 at 4:00 PM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date.

Analysts expect Zentalis Pharmaceuticals to post earnings of -$0.58 per share for Q3 2026.

Zentalis Pharmaceuticals Earnings Headlines

Zentalis Pharmaceuticals (NASDAQ:ZNTL) & Aquestive Therapeutics (NASDAQ:AQST) Financial Comparison
October 14 at 2:15 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31117376
Zentalis Pharmaceuticals Shares Rise After Leerink Upgrade
October 6, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/zentalis-pharmaceuticals-shares-rise-leerink-193231080.html
Your $29.97 book is free today
Why Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options can give you up to 12 times the leverage of stocks — with a fraction of the capital tied up. This free guide lays it all out in plain English — from A to Z, with step-by-step examples you can follow in your own account.tc pixel
October 15 at 1:00 AM  |  Profits Run (Ad)
Leerink Upgrades Zentalis Pharmaceuticals to Outperform From Market Perform, Price Target is $8
October 5, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/leerink-upgrades-zentalis-pharmaceuticals-outperform-110835452.html
Zentalis Pharmaceuticals (ZNTL) Gets a Hold from Wells Fargo
October 5, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/ZNTL/pressreleases/4897742/zentalis-pharmaceuticals-zntl-gets-a-hold-from-wells-fargo/
Zentalis Pharmaceuticals Shares Rise After Leerink Assumes Coverage With Outperform Rating
October 5, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/zentalis-pharmaceuticals-shares-rise-leerink-115556183.html
See More Zentalis Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Zentalis Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Zentalis Pharmaceuticals and other key companies, straight to your email.

About Zentalis Pharmaceuticals

Zentalis Pharmaceuticals (NASDAQ:ZNTL) (NASDAQ: ZNTL) is a clinical-stage biopharmaceutical company focused on discovering and developing small-molecule medicines for the treatment of cancer. The company’s research programs are designed to target biological pathways involved in tumor growth, survival and resistance to existing therapies.

Zentalis’ lead investigational product is azenosertib, also known as ZN-c3, an oral WEE1 inhibitor being evaluated in clinical trials for several advanced cancers. WEE1 is a cell-cycle regulator, and the company is studying whether inhibiting the protein can create therapeutic opportunities in tumors with specific genetic or molecular characteristics. Azenosertib remains an investigational therapy and has not been approved for commercial use.

The company was established in 2014 and became a publicly traded company in 2020. Zentalis conducts research and clinical development activities in the United States and through clinical trial networks that may include international sites. Its leadership includes Kimberly Blackwell, M.D., who serves as chief executive officer and has experience in oncology drug development and commercialization.

View Zentalis Pharmaceuticals Profile
Earnings Tools